Norbert Brüggemann, MD

1998-2005 Medical school (Lübeck, Luzern)

2001-2005 Doctoral thesis (Department of Experimental Pharmacology and Toxicology, University of Lübeck, Germany)

2005-2011 Medical residency (Dept. of Neurology, University of Lübeck, Germany)

2005-2011 Neurogenetics Research Fellow (Section of Clinical and Molecular Neurogenetics, University of Lübeck, Germany)

2011-2013 Postdoctoral fellow (Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Denmark)

2012 Habilitation in Neurogenetics (University of Lübeck, Germany)

2013-2014 Medical residency (Dept. of Neurology, University of Lübeck, Germany)
2012-2017 Assistant Professor in Neurogenetics

2014-present Neurology Consultant, head of the Movement Disorders Clinic (Dept. of Neurology, University of Lübeck, Germany)

Since 2017 Associate Professor of Neurology

2011-present Ad hoc reviewer for Annals of Neurology, Human Brain Mapping, Journal of Neurology Neurosurgery and Psychiatry, Lancet Psychiatry, Movement Disorders Journal, Neuroimage, Parkinsonism and Related Disorders, Scientific Reports (selection)

Member German Neurological Society (DGN), International Parkinson and Movement Disorder Society (MDS), American Academy of Neurology (AAN), German Parkinson Foundation, German Society for Clinical Neurophysiology and Functional Imaging (DGKN), study group ‘Botulinum toxin’ of the German Society of Neurology, study group ‘Deep brain stimulation’

2018-present Editorial Board of Parkinsonism and Related Disorders

2002 – 2005 Scholarship of the German Catholic Academic Foundation „Cusanuswerk“

2006 University Award of the Medical Faculty, University of Lübeck

2008 – 2012 5 travel grants from the Movement Disorder Society and the American Academy of Neurology

2012 Junior Research Award of the Movement Disorder Society

2017 Poster price (senior author), 10th German Congress for Parkinson’ Disease and Movement Disorders

2017 Gilberto Gamez Memorial Lecture, 12th ASNA Biennal Convention, 39th Annual PNA Convention. Metro Manila, Philippines

1. Djarmati A, Schneider SA, Lohmann K, Winkler S, Pawlack H, Hagenah J, Brüggemann N, Zittel S, Fuchs T, Raković A, Schmidt A, Jabusch HC, Wilcox R, Kostić VS, Siebner H, Altenmüller E, Münchau A, Ozelius LJ, Klein C. Mutations in THAP1 (DYT6) and generalised dystonia with prominent spasmodic dysphonia: a genetic screening study. Lancet Neurol 2009;8:447-452. [IF: 21.8]
2. Brüggemann N, Hagenah J, Reetz K, Schmidt A, Kasten M, Buchmann I, Eckerle S, Bähre M, Münchau A, Djarmati A, van der Vegt J, Siebner H, Binkofski F, Ramirez A, Behrens MI, Klein C. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol 2010;67:1357- 63. [IF: 7.0]
3. Hagenah J, König IR, Sperner J, Wessel L, Seidel G, Condefer K, Saunders-Pullman R, Klein C, Brüggemann N. Life-long increase of substantia nigra hyperechogenicity in transcranial sonography. Neuroimage 2010;51:28-32. [IF: 6.1]
4. Brüggemann N, Spiegler J, Hellenbroich Y, Opladen T, Schneider SA, Stephani U, Boor R, Gillessen-Kaesbach G, Sperner J, Klein C. Beneficial prenatal levodopa therapy in autosomal recessive GTP cyclohydrolase I deficiency. Arch Neurol 2012;69:1071-5. [IF: 7.0]
5. Brüggemann N, Kühn A, Schneider SA, Kamm C, Wolters A, Krause P, Moro E, Steigerwald F, Wittstock M, Tronnier V, Lozano AM, Hamani C, Poon YY, Zittel S, Wächter T, Deuschl G, Krüger R, Kupsch A, Münchau A, Lohmann K, Volkmann J, Klein C. Short- and long-term outcome of chronic pallidal neurostimulation in monogenic isolated dystonia. Neurology 2015;84:895-903. [IF: 8.3]
6. Heldmann M, Heeren J, Klein C, Rauch L, Hagenah J, Münte TF, Kasten M, Brüggemann N. Neuroimaging Abnormalities in Individuals Exhibiting Parkinson’s Disease Risk Markers. Mov Disord 2018;33:1412-1422. [IF3]
7. Brüggemann N, Domingo A, Rasche D, Moll CKE, Rosales RL, Jamora RDG, Hanßen H, Münchau A, Graf J, Weissbach A, Tadic V, Diesta CC, Volkmann J, Kühn AA, Münte TF, Tronnier V, Klein C. Short- and long-term effects of pallidal neurostimulation and outcome predictors in X-linked dystonia- parkinsonism. JAMA Neurol 2019;76:211-216.[IF: 12.3]
8. Hanssen H, Heldmann M, Prasuhn J, Tronnier V, Rasche D, Diesta C, Domingo A, Rosales R, Jamora R, Klein C, Münte T, Brüggemann N. Basal ganglia and cerebellar pathology in X-linked dystonia- parkinsonism. Brain 2018;141:2995-3008. [IF: 11.8]
9. Westenberger A, Reyes CJ, Saranza G, Dobricic V, Hanssen H, Domingo A, Laabs BH, Schaake S, Pozojevic J, Rakovic A, Grütz K, Begemann K, Walter U, Dressler D, Bauer P, Rolfs A, Münchau A, Kaiser FJ, Ozelius LJ, Jamora RD, Rosales RL, Diesta CCE, Lohmann K, König IR, Brüggemann N, Klein C. A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism. Ann Neurol 2019;85:812-822. [IF: 9.5]
10. Hanssen H, Prasuhn J, Heldmann M, Diesta CC, Domingo A, Göttlich M, Blood AJ, Rosales RL, Jamora RDG, Münte TF, Klein C, Brüggemann N. Imaging gradual neurodegeneration in a basal ganglia model disease. Ann Neurol 2019;86:517-526. [IF: 9.5]